Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trametinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 known ✓ | Q02750 | 17/20 | 1.00 |
| ▸ | MAP2K2 known ✓ | P36507 | 2/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.37 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trametinib SCHEMBL29363416 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL29355100 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL1419085 | 0.99 | MAP2K1 (0.98) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL1419395 | 0.99 | MAP2K1 (0.98) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL21048481 | 0.99 | MAP2K1 (0.98) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL1419392 | 0.99 | MAP2K1 (0.98) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL30035834 | 0.99 | MAP2K1 (0.98) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL30301264 | 0.99 | MAP2K1 (0.98) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL1419017 | 0.98 | MAP2K1 (0.97) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| SCHEMBL26815709 | 0.98 | MAP2K1 (0.96) | MAP2K1MAP2K2ABCB1NOX4PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 15624 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146289-A1 | ASSESSING AND TREATING MELANOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2026-05-28 | — | — | US | claimed |
| EP-4747285-A1 | MONOCLONAL ANTIBODIES AGAINST PCDH7 FOR LUNG CANCER THERAPY | The Board of Regents of the University of Texas System (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| US-12636376-B2 | Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors | IN3BIO LTD. (BM) | 2026-05-26 | — | — | US | claimed |
| CN-115813930-B | Use of macrocyclic compounds in combination with MEK inhibitors in medicaments for the treatment of diseases | Sano Hubble Pharmaceutical (Chengdu) Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-122070932-A | Application of combination of decitabine and anti-HER 2 antibody in preparation of medicines for treating tumors | 上海交通大学 | 2026-05-22 | — | — | CN | claimed |
| WO-2026107416-A1 | SINGLE DOSAGE FORMS CONTAINING ELRAGLUSIB AND AT LEAST ONE OTHER ACTIVE INGREDIENT | ACTUATE THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260139320-A1 | StarTrace: A Multiplex Drug Testing Platform for Personalized Medicine | UNIV OF SOUTH CAROLINA (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| EP-2571358-A1 | COMBINATION | GlaxoSmithKline LLC (US) | 2013-03-27 | — | — | EP | claimed |
| US-20120245180-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2012-09-27 | — | — | US | claimed |
| EP-2482819-A2 | COMBINATION | GlaxoSmithKline LLC (US) | 2012-08-08 | — | — | EP | claimed |
| WO-2012088033-A2 | NOVEL PHARMACEUTICAL COMPOSITION | GLAXOSMITHKLINE LLC (US) | 2012-06-28 | — | — | WO | claimed |
| WO-2012088030-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2012-06-28 | — | — | WO | claimed |
| WO-2012027438-A1 | PHARMACEUTICAL COMBINATION OF A VEGFR INHIBITOR AND A MEK INHIBITOR USEFUL FOR TREATING CANCER | GLAXOSMITHKLINE LLC (US) | 2012-03-01 | — | — | WO | claimed |
| WO-2011146712-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2011-11-24 | — | — | WO | claimed |
| WO-2011038380-A2 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2011-03-31 | — | — | WO | claimed |
| US-7378423-B2 | Antiproliferative, anticancer, antitumor agents; rheumatism; N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]-phenyl}-acetamide; a p15, and/or a protein inducing action, and/or an MEK inhibitory action; side effect reduction | JAPAN TOBACCO INC. (JP) | 2008-05-27 | — | — | US | claimed |
| EP-1761528-B1 | 5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CANCER | JAPAN TOBACCO INC (JP) | 2008-01-09 | — | — | EP | claimed |